Safety Signals Force Enanta To Stop EDP-721 HBV Program

  • Enanta Pharmaceuticals Inc ENTA has decided to discontinue the development of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer.
  • The move follows safety signals observed in the single ascending dose part of a Phase 1 study in healthy volunteers.
  • "Despite the clean preclinical safety profile demonstrated in comprehensive toxicology studies, safety signals were seen in healthy subjects after administration of EDP-721. 
  • The Company will continue to focus on developing EDP-514 in combination regimens as a functional cure for HBV.
  • Related: Enanta To Discontinue Internal Development Of NASH Candidates.
  • Price Action: ENTA shares closed at $92.58 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsHepatits BPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!